Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elizabeth R Gerstner

Showing results (121-130 of 133) with videos related to

Pageof 14
Sort By:
Nature Medicine|June 2, 2023
Pembrolizumab in brain metastases of diverse histologies: phase 2 trial resultsPriscilla K Brastianos, Albert E Kim, Anita Giobbie-Hurder, et al.
Nature Medicine|June 20, 2020
Publisher Correction: Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosisPriscilla K Brastianos, Eudocia Quant Lee, Justine V Cohen, et al.
Nature Medicine|January 16, 2026
Abemaciclib in meningiomas with somatic NF2 or CDK pathway alterations: the phase 2 Alliance A071401 trialPriscilla K Brastianos, Katharine Dooley, Susan Geyer, et al.
Neuro-Oncology Advances|February 6, 2025
Ivosidenib for the treatment of IDH1-mutant glioma, grades 2-4: Tolerability, predictors of response, and outcomesTyler A Lanman, Gilbert Youssef, Raymond Huang, et al.
Nature Communications|October 13, 2021
Phase II study of ipilimumab and nivolumab in leptomeningeal carcinomatosisPriscilla K Brastianos, Matthew R Strickland, Eudocia Quant Lee, et al.
Nature Medicine|June 3, 2020
Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosisPriscilla K Brastianos, Eudocia Quant Lee, Justine V Cohen, et al.
JCO Precision Oncology|September 14, 2020
Exploring Predictors of Response to Dacomitinib in <i>EGFR</i>-Amplified Recurrent GlioblastomaAndrew S Chi, Daniel P Cahill, David A Reardon, et al.
Neuro-Oncology|June 28, 2025
Mesothelin is a surface antigen present on human meningioma and can be effectively targeted by CAR T-cellsRishab Ramapriyan, Fred G Barker, Leland G Richardson, et al.
Neuro-Oncology|December 9, 2023
Abnormal vascular structure and function within brain metastases is linked to pembrolizumab resistanceAlbert E Kim, Kevin W Lou, Anita Giobbie-Hurder, et al.
Biorxiv : the Preprint Server for Biology|September 11, 2023
Structural and functional vascular dysfunction within brain metastases is linked to pembrolizumab inefficacyAlbert E Kim, Kevin W Lou, Anita Giobbie-Hurder, et al.
Pageof 14

Showing results (121-130 of 133) with videos related to

Sort By:
Pageof 14
Nature Medicine|June 2, 2023
Pembrolizumab in brain metastases of diverse histologies: phase 2 trial resultsPriscilla K Brastianos, Albert E Kim, Anita Giobbie-Hurder, et al.
Nature Medicine|June 20, 2020
Publisher Correction: Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosisPriscilla K Brastianos, Eudocia Quant Lee, Justine V Cohen, et al.
Nature Medicine|January 16, 2026
Abemaciclib in meningiomas with somatic NF2 or CDK pathway alterations: the phase 2 Alliance A071401 trialPriscilla K Brastianos, Katharine Dooley, Susan Geyer, et al.
Neuro-Oncology Advances|February 6, 2025
Ivosidenib for the treatment of IDH1-mutant glioma, grades 2-4: Tolerability, predictors of response, and outcomesTyler A Lanman, Gilbert Youssef, Raymond Huang, et al.
Nature Communications|October 13, 2021
Phase II study of ipilimumab and nivolumab in leptomeningeal carcinomatosisPriscilla K Brastianos, Matthew R Strickland, Eudocia Quant Lee, et al.
Nature Medicine|June 3, 2020
Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosisPriscilla K Brastianos, Eudocia Quant Lee, Justine V Cohen, et al.
JCO Precision Oncology|September 14, 2020
Exploring Predictors of Response to Dacomitinib in <i>EGFR</i>-Amplified Recurrent GlioblastomaAndrew S Chi, Daniel P Cahill, David A Reardon, et al.
Neuro-Oncology|June 28, 2025
Mesothelin is a surface antigen present on human meningioma and can be effectively targeted by CAR T-cellsRishab Ramapriyan, Fred G Barker, Leland G Richardson, et al.
Neuro-Oncology|December 9, 2023
Abnormal vascular structure and function within brain metastases is linked to pembrolizumab resistanceAlbert E Kim, Kevin W Lou, Anita Giobbie-Hurder, et al.
Biorxiv : the Preprint Server for Biology|September 11, 2023
Structural and functional vascular dysfunction within brain metastases is linked to pembrolizumab inefficacyAlbert E Kim, Kevin W Lou, Anita Giobbie-Hurder, et al.
Pageof 14